Skip to content

D-chiro-Inositol in Overweight Type 1 Diabetes Patients

A Pilot Study of D-Chiro-Inositol Plus Folic Acid in Overweight Patients With Type 1 Diabetes

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02730949
Enrollment
26
Registered
2016-04-07
Start date
2014-03-31
Completion date
2015-12-31
Last updated
2016-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes

Keywords

D-Chiro-Inositol, type 1 diabetes

Brief summary

The purpose of this pilot study was to evaluate the effect of D-chiro-Inositol (DCI) oral supplementation in addiction to folic acid compared to folic acid alone on glycaemic control as assessed by HbA1c in overweight or obese T1D patients undergoing intensive insulin therapy. A 24 weeks, prospective, randomized control trial was carried out in T1D patients, aged 17-50 years (13 males, 13 females), with disease duration \> 1 year and BMI \>25, attending as outpatients the Endocrinology and Diabetes Unit of University Campus Bio-Medico in Rome

Interventions

DIETARY_SUPPLEMENTD-chiro-inositol

Treated group

DIETARY_SUPPLEMENTFolic Acid

Control group

Sponsors

Campus Bio-Medico University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
17 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* T1D patients * aged 17-50 years * disease duration \> 1 year * BMI \>25

Exclusion criteria

* learning disabilities * presence of chronic conditions potentially able to influence daily activities (visual or auditory disability, motor impairment for neurological or orthopaedic problems). * T1D patients affected from diabetic complications * pregnancy

Design outcomes

Primary

MeasureTime frameDescription
efficacy of DCI oral supplementation on metabolic control6 monthsefficacy of DCI oral supplementation on metabolic control as assessed by HbA1c (%)

Secondary

MeasureTime frameDescription
BMI kg/m26 monthsreduction of BMI
Insulin Requirement (I.R.) IU/kg6 monthsreduction of I.R.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 11, 2026